| Literature DB >> 20394721 |
Germaine Hanquet1, Anne Perrocheau, Esther Kissling, Daniel Levy Bruhl, David Tarragó, James Stuart, Pawel Stefanoff, Sigrid Heuberger, Paula Kriz, Anne Vergison, Sabine C de Greeff, Andrew Amato-Gauci, Lucia Pastore Celentano.
Abstract
In this era of new pneumococcal conjugate vaccines (PCV), we described and compared surveillance of invasive pneumococcal disease (IPD) and PCV policies in 30 European countries to provide guidance for Europe-wide surveillance. We confirmed the heterogeneity of surveillance systems and case definitions across countries but identified elements common to all countries, such as the availability of serotyping and the surveillance of pneumococcal meningitis. PCV impact was monitored in 11/15 countries using it. We propose steps for the monitoring of incidence rates and serotype distribution at EU level, to assess the need to introduce PCV and monitor its impact once introduced. Copyright 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20394721 DOI: 10.1016/j.vaccine.2010.03.069
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641